NSAID use and risk of Parkinson disease: A population-based case-control study

European Journal of Neurology

Volumn 18, Issue 11, 2011, Pages 1336-1342

  Becker, C ^a   Jick, S S ^b   Meier, C R ^a,b,c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Case control analysis; Epidemiology; Non steroidal anti inflammatory drugs; Parkinson disease

Indexed keywords

ACECLOFENAC; ACEMETACIN; ACETYLSALICYLIC ACID; AZAPROPAZONE; DIFLUNISAL; ETODOLAC; FENBUFEN; FENOPROFEN; FLUFENAMIC ACID; FLURBIPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LORNOXICAM; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NIMESULIDE; OXYPHENBUTAZONE; PARACETAMOL; PHENYLBUTAZONE; PIROXICAM; SULINDAC; TENOXICAM; TIAPROFENIC ACID; TOLFENAMIC ACID; TOLMETIN;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENERAL PRACTICE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POPULATION BASED CASE CONTROL STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK; SEX;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DYSKINESIA, DRUG-INDUCED; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SWITZERLAND;

EID: 79958116313     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03399.x     Document Type: Article

References (33)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-2066.
2. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-397.
3. Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001; 39: 167-174.
4. Etminan M, Carleton BC, Samii A. Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. J Clin Neurosci 2008; 15: 576-577.
5. Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord 2008; 23: 88-95.
6. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 2007; 69: 1836-1842.
7. Bornebroek M, de Lau LM, Haag MD, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 2007; 28: 193-196.
8. Hancock DB, Martin ER, Stajich JM, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 2007; 64: 576-580.
9. Bower JH, Maraganore DM, Peterson BJ, Ahlskog JE, Rocca WA. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 2006; 67: 494-496.
10. Etminan M, Suissa S. NSAID use and the risk of Parkinson's disease. Curr Drug Saf 2006; 1: 223-225.
11. Ton TG, Heckbert SR, Longstreth WT Jr, et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 2006; 21: 964-969.
12. Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005; 58: 963-967.
13. Chen H, Zhang SM, Hernán MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; 60: 1059-1064.
14. Hernán MA, Logroscino G, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 2006; 66: 1097-1099.
15. Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010; 74: 995-1002.
16. Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009; 26: 769-779.
17. Wood L, Martinez C. The general practice research database: role in pharmacovigilance. Drug Saf 2004; 27: 871-881.
18. Walley T, Mantgani A. The UK general practice research database. Lancet 1997; 350: 1097-1099.
19. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-689.
20. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the general practice research database: a systematic review. Br J Gen Pract 2010; 60: e128-e136.
21. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol 2010; 69: 4-14.
22. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Eng J Med 2007; 356: 29-38.
23. Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008; 70(16 Pt 2): 1438-1444.
24. Pahwa R, Lyons KE. Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines. Am J Manag Care 2010;16 (Suppl. Implications) S94-S99.
25. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatr 2008; 79: 368-376.
26. Mena MA, de Yébenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf 2006; 5: 759-771.
27. Alvarez MV, Evidente VG. Understanding drug-induced parkinsonism: separating pearls from oysters. Neurology 2008; 70: e32-e34.
28. Ascherio A, Tanner CM. Use of antihypertensives and the risk of Parkinson disease. Neurology 2009; 72: 578-579.
29. Defazio G, Berardelli A, Fabbrini G, et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol 2008; 65: 1191-1194.
30. O'Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord 2008; 23: 101-106.
31. Riley D, Lang AE, Blair RD, Birnbaum A, Reid B. Frozen shoulder and other shoulder disturbances in Parkinson's disease. J Neurol Neurosurg Psychiatr 1989; 52: 63-66.
32. Hernán MA, Logroscino G, Rodríguez LA. A prospective study of alcoholism and the risk of Parkinson's disease. J Neurol 2004; 251(Suppl. 7): vII14-vII17.
33. Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002; 22: 303-309.